ABLYNX
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.
ABLYNX
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2001-01-01
Address:
Zwijnaarde, Oost-Vlaanderen, Belgium
Country:
Belgium
Website Url:
http://www.ablynx.com
Total Employee:
251+
Status:
Active
Contact:
(092) 620-000_
Total Funding:
498.78 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS Google Maps API Mimecast Adobe Enterprise Cloud Verisign Seal
Similar Organizations
Acacia Pharma
Acacia Pharma is a pharmaceutical company engaged in the R&D of supportive care drugs for cancer patients.
Almac Group
Almac is a financially secure, privately owned organisation with over 4,500 employees located within the US, Europe and Asia.
Ark Biosciences
Ark Biosciences is a biopharmaceutical company that is dedicated to the discovery and development
BioNTech
BioNTech is a biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Kiadis Pharma
Kiadis Pharma is a biopharmaceutical company offering novel treatment options for terminally ill cancer patients.
Skye Bioscience
Skye Bioscience is a biopharmaceutical company focused on the discovery, development, and the commercialization.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Palau Pharma S.A.
PALAU PHARMA is a newly created biopharmaceutical company, whose mission is the discovery and development of drug candidates.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Pomona Ricera
This company is a private discovery-stage biotech company engaged in the design, development and production.
Proacta Therapeutics
Proacta Therapeutics is a biopharmaceutical company, engages in the discovery and development of oncology drugs.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Peter Fellner Chairman of the Board @ Ablynx
Chairman of the Board
Founder
Stock Details
Investors List
Gimv
Gimv investment in Grant - Ablynx
Jefferies
Jefferies investment in Post-IPO Equity - Ablynx
KBC Securities
KBC Securities investment in Post-IPO Equity - Ablynx
Kempen & Co
Kempen & Co investment in Post-IPO Equity - Ablynx
KBC
KBC investment in Series C - Ablynx
Abingworth
Abingworth investment in Series C - Ablynx
Biotech Fund Flanders
Biotech Fund Flanders investment in Series C - Ablynx
Gilde Healthcare
Gilde Healthcare investment in Series C - Ablynx
Sofinnova Partners
Sofinnova Partners investment in Series C - Ablynx
Gimv
Gimv investment in Series C - Ablynx
Official Site Inspections
http://www.ablynx.com
- Host name: ec2-54-247-151-159.eu-west-1.compute.amazonaws.com
- IP address: 54.247.151.159
- Location: Dublin Ireland
- Latitude: 53.3338
- Longitude: -6.2488
- Timezone: Europe/Dublin
- Postal: D02
More informations about "Ablynx"
Ablynx - Crunchbase Company Profile & Funding
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody …See details»
Ablynx - Wikipedia
In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2 million was provided by Gimv. In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion — having made an unreported offer in mid-December for the company. However, the Ablynx board rejected this offer the same day, saying that the price undervalued the business. See details»
Ablynx Company Profile - Office Locations, Competitors ... - Craft
Oct 22, 2018 Ablynx €85.19 m in annual revenue in FY 2016. See insights on Ablynx including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Ablynx - LinkedIn
Ablynx | 17,853 followers on LinkedIn. Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, …See details»
Ablynx Company Profile | Gent, Belgium - Dun & Bradstreet
Company Description: Belgian biopharma firm Ablynx is focused on developing and commercializing its Nanobody technology platform. Nanobodies are engineered proteins with …See details»
Ablynx nv - Gent, Belgium - bionity.com
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on …See details»
Ablynx - Products, Competitors, Financials, Employees, …
Ablynx specializes in the development of nanobodies, a class of proprietary therapeutic proteins in the biotechnology and pharmaceutical industry. Use the CB Insights Platform to explore …See details»
Ablynx Company Profile 2024: Valuation, Investors, Acquisition
Information on acquisition, funding, cap tables, investors, and executives for Ablynx. Use the PitchBook Platform to explore the full profile.See details»
Ablynx - Gilde Healthcare
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the …See details»
Ablynx - Funding, Financials, Valuation & Investors - Crunchbase
Ablynx is a biopharmaceutical company engaged in the discovery and development of nanobodies.See details»
Sanofi to acquire Ablynx for €3.9 Billion
Jan 29, 2007 Sanofi to acquire Ablynx for €3.9 Billion . Strengthens Sanofi's R&D strategy with innovative Nanobody ® technology platform. Expands growing rare blood disorders franchise …See details»
IR call - Acquisition of Ablynx - Sanofi
Jan 29, 2018 Additional Information for US investors. The tender offer for the outstanding ordinary shares (“Shares”), American Depositary Shares issued by J.P. Morgan Chase Bank, …See details»
Sanofi Completes $4.8-Billion Ablynx Acquisition - pharmtech.com
Jun 20, 2018 Sanofi announced on June 19, 2018 that it has completed its $4.8-billion acquisition of Ablynx, a biopharmaceutical company based in Ghent, Belgium, that develops …See details»
Ablynx NV — Sofinnova Partners
Ablynx NV [ABLX] is focused on the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range …See details»
Ablynx | Case study | Invest Europe
Oct 3, 2019 Originally funded by VIB (a research institute) and GIMV, Ablynx raised €70m over the next 6 years from Sofinnova, Gilde, Alta Partners, Abingworth and KBC.See details»
Ablynx - Recent News & Activity - Crunchbase
Apr 4, 2019 Organization. Ablynx . Connect to CRM . Save . Go back to Ablynx's Signals & News . Recent News & Activity. Edit Recent News & Activity Section. Number of Articles 145.See details»
Ablynx's nanobody fragments go places antibodies cannot
Dec 8, 2017 “My general perception is the default option is the full-length antibody,” says Janice Reichert, executive director of The Antibody Society, a non-profit organization based in …See details»
Ablynx - Abingworth LLP
Ablynx is discovering and developing novel, proprietary antibody-like molecules called nanobodies. These nanobodies are being developed both as target validation tools and as …See details»
Ablynx files rare blood disorder drug, raising prospect of first ...
Feb 6, 2017 The drug could be the first commercial product for Ablynx, which is one of Europe's top-tier biotechs, employing around 400 people and with eight programs in clinical trials.See details»
About ABB - ABB Group
Building on over 140 years of excellence, our more than 105,000 employees worldwide are committed to delivering on our purpose with innovations that create success for ABB and all …See details»